{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:28:50Z","timestamp":1777498130466,"version":"3.51.4"},"reference-count":37,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Sciences and Technology of Japan","award":["24K11431 (YI)"],"award-info":[{"award-number":["24K11431 (YI)"]}]},{"name":"Ministry of Education, Culture, Sports, Sciences and Technology of Japan","award":["H24-011 (HN)"],"award-info":[{"award-number":["H24-011 (HN)"]}]},{"name":"Science Research Promotion Fund from the Promotion, Kitasato University Medical Center","award":["24K11431 (YI)"],"award-info":[{"award-number":["24K11431 (YI)"]}]},{"name":"Science Research Promotion Fund from the Promotion, Kitasato University Medical Center","award":["H24-011 (HN)"],"award-info":[{"award-number":["H24-011 (HN)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Many large-scale studies revealed that exogenous erythropoietin, erythropoiesis-stimulating agents, have no renoprotective effects. We reported the renoprotective effects of endogenous erythropoietin production on renal function in ischemic reperfusion injury (IRI) of the kidney using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat. The purpose of this study was to investigate the effects of daprodustat on the progression of chronic renal failure. We retrospectively investigated the effects of daprodustat on the progression of chronic renal failure and renal anemia in patients with stages 3a-5 chronic kidney diseases (estimated glomerular filtration rate, eGFR &lt; 60 mL\/min\/1.73 m2). The results show that daprodustat largely slowed the reduction in eGFR. The recovery of renal function was observed in some patients. Daprodustat is useful not only for renal anemia but also for the preservation of renal function. The renoprotective effect of daprodustat was small in patients with serum creatinine larger than 3\u20134 mg\/dL because of low residual renal function. The appearance of renal anemia would be a sign of the time to start using daprodustat.<\/jats:p>","DOI":"10.3390\/ijms25179468","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T09:56:42Z","timestamp":1725357402000},"page":"9468","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia"],"prefix":"10.3390","volume":"25","author":[{"given":"Yoshitaka","family":"Shimada","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-9619","authenticated-orcid":false,"given":"Yuichiro","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-1653","authenticated-orcid":false,"given":"Yukiko","family":"Yasuoka","sequence":"additional","affiliation":[{"name":"Department of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nagaba","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Nanami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya 663-8501, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-0607","authenticated-orcid":false,"given":"Jeff M.","family":"Sands","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Emory University School of Medicine, 1639 Pierce Drive, WMB Room 1107, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-1690","authenticated-orcid":false,"given":"Noriko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumasa","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-7380","authenticated-orcid":false,"given":"Hiroshi","family":"Nonoguchi","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan"},{"name":"Nephrology, Internal Medicine, Sagamihara Red-Cross Hospital, 256 Nakano, Midori-ku, Sagamihara 252-0157, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/313806a0","article-title":"Isolation and characterization of genomic and cDNA clones of human erythropoietin","volume":"313","author":"Jacobs","year":"1985","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/S0021-9258(19)63387-9","article-title":"Purification of human erythropoietin","volume":"252","author":"Miyake","year":"1977","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1203165","article-title":"Peginesatide in patients with anemia undergoing hemodialysis","volume":"368","author":"Fishbane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","article-title":"Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors","volume":"82","author":"Locatelli","year":"2022","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/TCRM.S293879","article-title":"Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease","volume":"17","author":"Ishii","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000504850","article-title":"Treatment of Renal Anemia with Roxadustat: Advantages and Achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/1744-9987.13839","article-title":"Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan","volume":"26","author":"Nangaku","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Elliott, S., Tomita, D., and Endre, Z. (2017). Erythropoiesis stimulating agents and reno-protection: A meta-analysis. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0438-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10157-020-02005-4","article-title":"Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: A multicenter open-label randomized controlled study","volume":"25","author":"Tsuruya","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yasuoka, Y., Izumi, Y., Fukuyama, T., Oshima, T., Yamazaki, T., Uematsu, T., Kobayashi, N., Nanami, M., Shimada, Y., and Nagaba, Y. (2024). Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021223"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Odawara, M., Nishi, H., and Nangaku, M. (2024). A spotlight on using HIF-PH inhibitors in renal anemia. Expert. Opin. Pharmacother., 1\u20139.","DOI":"10.1080\/14656566.2024.2378903"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1681\/ASN.2022040413","article-title":"Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?","volume":"33","author":"Locatelli","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1159\/000148256","article-title":"Hypoxia and hypoxia-inducible factor in renal disease","volume":"110","author":"Nangaku","year":"2008","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14485","DOI":"10.14814\/phy2.14485","article-title":"Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation","volume":"8","author":"Yasuoka","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e05389","DOI":"10.1016\/j.heliyon.2020.e05389","article-title":"Differentiation of endogenous erythropoietin and exogenous ESAs by Western blotting","volume":"6","author":"Yasuoka","year":"2020","journal-title":"Heliyon"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Yasuoka, Y., Izumi, Y., Sands, J.M., Kawahara, K., and Nonoguchi, H. (2023). Progress in the Detection of Erythropoietin in Blood, Urine, and Tissue. Molecules, 28.","DOI":"10.3390\/molecules28114446"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bin, S., Cantarelli, C., Horwitz, J.K., Gentile, M., Podest\u00e0, M.A., La Manna, G., Heeger, P.S., and Cravedi, P. (2023). Endogenous erythropoietin has immunoregulatory functions that limit the expression of autoimmune kidney disease in mice. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1195662"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2022.8801","article-title":"Association of Estimated GFR Calculated Using Race-Free Equations with Kidney Failure and Mortality by Black vs. Non-Black Race","volume":"327","author":"Sang","year":"2022","journal-title":"Jama"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2215\/CJN.0000000000000050","article-title":"Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD","volume":"18","author":"Collier","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yasuoka, Y., Izumi, Y., Fukuyama, T., Omiya, H., Pham, T.D., Inoue, H., Oshima, T., Yamazaki, T., Uematsu, T., and Kobayashi, N. (2022). Effects of Roxadustat on Erythropoietin Production in the Rat Body. Molecules, 27.","DOI":"10.3390\/molecules27031119"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia","volume":"55","author":"Packer","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1096\/fj.05-3820fje","article-title":"Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor","volume":"19","author":"Kato","year":"2005","journal-title":"Faseb J."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kato, H., Ishida, J., Matsusaka, T., Ishimaru, T., Tanimoto, K., Sugiyama, F., Yagami, K., Nangaku, M., and Fukamizu, A. (2015). Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129484"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.vh.2017.02.001","article-title":"Erythropoietin Regulation by Angiotensin II","volume":"105","author":"Kim","year":"2017","journal-title":"Vitam. Horm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/mol.113.091157","article-title":"Mechanism of erythropoietin regulation by angiotensin II","volume":"85","author":"Kim","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yasuoka, Y., Izumi, Y., Fukuyama, T., Inoue, H., Oshima, T., Yamazaki, T., Uematsu, T., Kobayashi, N., Shimada, Y., and Nagaba, Y. (2021). Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver. Molecules, 26.","DOI":"10.3390\/molecules26175399"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.bbrc.2018.08.102","article-title":"Fludrocortisone stimulates erythropoietin production in the intercalated cells of the collecting ducts","volume":"503","author":"Yasuoka","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.ajkd.2007.09.004","article-title":"Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan","volume":"50","author":"Imai","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"(2024). Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin. Exp. Nephrol., 28, 473\u2013495.","DOI":"10.1007\/s10157-024-02497-4"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:46:04Z","timestamp":1760111164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":37,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179468"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179468","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}